Enhancer-targeted CRISPR-A rescues haploinsufficiency and mutant phenotypes in organoid models of autism

Authors:

Abstract
Autism spectrum disorder (ASD) is a highly heritable condition with diverse clinical presentations. Approximately 15% of the genetic susceptibility of ASD is imparted by de novo haploinsufficient mutations of major effect. We mapped enhancers of two high-confidence autism genes, CHD8 and SCN2A , and used CRISPR-based gene activation targeting enhancers (eCRISPR-A) in human pluripotent stem cell (hPSC)-derived excitatory neurons and cerebral forebrain organoids to correct the effects of haploinsufficiency, taking advantage of the presence of a wild-type allele of each gene and endogenous gene regulation. Here we show that eCRISPR-A induced a sustained increase in CHD8 and SCN2A expression specifically in mutant neurons and cortical organoids, with rescue of gene expression levels and mutation-associated phenotypes, including gene expression and physiology. These data support gene activation via targeting enhancers of haploinsufficient genes as a therapeutic intervention in ASD and other neurodevelopmental disorders.
Funding Information
  • National Institute of Mental Health (R01MH10027)
  • National Institute of Mental Health (U01MH116489)
  • National Institute of Mental Health (F32MH124337)
  • Simons Foundation (675474)
  • Simons Foundation (675474)
  • Simons Foundation (675474)
  • Simons Foundation (896724)
  • Simons Foundation (896724)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD103557)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD103557)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD103557)
  • Eagles Autism Foundation, pilot grant